home > ict > autumn 2019 > a decentralised ecosystem
International Clinical Trials

A Decentralised Ecosystem

Digital disruption in clinical research has been a constant for over 20 years; however, ensuring that this is still relevant where ‘the rubber hits the road’ has been a challenge (or roadblock, sticking with the metaphor). Following my recent attendance at the annual conference of the Society of Clinical Data Managers, I believe the momentum is now greater, and there is an appetite for change. This change is to how and where we capture and analyse the valuable data that are provided by human subjects who volunteer to take part in clinical trials.

Of many presentations and panel discussions, there was so much enthusiasm from inquisitive minds in our industry. While the day-to-day work of clinical research is pressurised, the professionals and experts in our industry are determined to advance processes that can improve data quality, reduce the risks on clinical trials, and improve safety and outcomes for patients, while also working to increase efficiency through cost and cycle time reductions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Ian O’Shaughnessy has over 22 years of experience in clinical research working at CROs. The first part of his career was spent in roles of increasing responsibility in clinical data management and programming. This included leading regional data management organisations for ICON in Europe and Asia Pacific. Since 2013, Ian has worked in the field of risk-based monitoring, developing ICON’s methodology, processes, and systems. He has worked directly with sponsor companies on early engagement and implementing risk-based clinical strategies. Ian holds a Bachelor’s in Genetics from Trinity College Dublin, Ireland, and postgraduate qualifications in Business, Management, and Information Technology.

Print this page
Send to a friend
Privacy statement
News and Press Releases

A new market reference added to Safe’n’Sound®, our passive safety device platform

Safe’n’Sound® is on the market in Europe with a newly registered injectable medication. The commercial launch of HULIO™ (Adalimumab Biosimilar) was initiated in selected European markets on October 19,2018. Hulio™, developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. is approved as a biosimilar for the same indications as the reference product, Humira®.
More info >>

White Papers

Spotlight on Quality in Study Startup

Oracle Health Sciences

This white paper addresses the growing interest in quality in clinical trial execution and how workflows play an essential role by building in the steps needed to comply with TMF guidelines, reducing downstream problems. This proactive strategy limits issues caused by siloes, yielding process improvements measurable by performance metrics.
More info >>

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement